checkAd

     508  0 Kommentare Asthma & COPD Market Report 2016-2026

    LONDON, October 27, 2016 /PRNewswire/ --

    Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs

    Visiongain's comprehensive new 313 page report reveals that the global asthma & COPD market will achieve revenues of $33.2bn in 2016.

    Are you involved in the asthma & COPD market or intend to be? If so, then you must read this report.
    It's vital that you keep your knowledge up to date. You need this report.

    Market scope: Asthma & COPD are among the most common and debilitating respiratory conditions. Drugs for the treatment of these conditions fall into 3 main categories: Bronchodilator monotherapy, anti-inflammatory drugs and combination drugs. Visiongain assesses how these three submarkets and the 12 largest national markets will evolve over the forecast period.The competitive landscape is further illustrated with examination of the 7 market leading manufacturers.

    The asthma & COPD Market 2016-2026 report responds to your need for definitive market data: 

    • Where are the asthma & COPD market opportunities?
    - 248 tables, charts, and graphs reveal market data allowing you to target your strategy more effectively

    • When will the asthma & COPD market grow?
    - Global, regional and asthma & COPD submarket forecasts and analysis from 2016-2026 illustrate the market progression

    • Which asthma & COPD submarkets will flourish from 2016-2026?
    - Individual application forecasts and analysis demonstrate the prospects
    • Combination drugs forecast 2016-2026
    • Anti-inflammatory drugs forecast 2016-2026
    - Corticosteroids forecast 2016-2026
    - Anti-Leukotrienes forecast 2016-2026
    - Monoclonal antibodies forecast 2016-2026
    - Other anti-inflammatories forecast 2016-2026
    • Bronchodilator monotherapy forecast 2016-2026
    - Short-acting beta2-agonist (SABAs) forecast 2016-2026
    - Long-acting beta2-agonist (LABAs) forecast 2016-2026
    - Anticholinergics forecast 2016-2026

    To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

    • Where are the regional asthma & COPD market opportunities from 2016-2026?
    - Focused regional forecasts and analysis explore the future opportunities
    - US forecast 2016-2026,
    - China forecast 2016-2026
    - Japan forecast 2016-2026
    - India forecast 2016-2026

    Seite 1 von 2



    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Asthma & COPD Market Report 2016-2026 LONDON, October 27, 2016 /PRNewswire/ - Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs …